Literature DB >> 22942564

Hematopoietic stem cell transplantation in a very high risk group of patients with the support of granulocyte transfusion.

Idil Yenicesu, Gülsan Sucak, Günter Dilsiz, Sahika Zeynep Akı, Zeynep Arzu Yeğin.   

Abstract

High risk patients with active fungal infection who had undergone hematopoietic stem cell transplantation (HSCT) with the support of granulocyte transfusions (GTX) as an adjunct to antifungal agents are reviewed retrospectively. Patients requiring immediate allogeneic HSCT for their primary hematological disorders (two severe aplastic anemia, one T cell acute lymphoblastic leukemia (ALL) in second complete remission, one acute myeloid leukemia (AML)-in first complete remission, one T-ALL in refractory relapse) but were denied by other transplant programs due to active invasive fungal infections had undergone HSCT with the support of GTX at the stem cell transplantation unit of Gazi University. Five patients who had undergone six transplants were included in the study and received a total of 38 (3-13) granulocyte transfusions during these six transplants. The median granulocyte concentration was 3.4 × 10(11) per apheresis bag. Full clinical and radiological recovery was achieved in three of the five high risk patients with active invasive fungal infection with the combination of antifungal agents and GTX. Even a very high risk patient with aplastic anemia who had undergone two consecutive transplants due to secondary graft failure was also cured of his primary disease despite the presence of multiple pulmonary fungus balls. Three of the five patients with very high risk features due to the underlying hematological disease and the associated active fungal infection were rescued with allogeneic HSCT performed with the support of GTX combined with antifungal agents. Despite the limitations of this report due to its retrospective nature, it suggests that GTX might be an alternative in patients with active fungal infections who otherwise are denied by the transplant programs. However, prospective randomized studies are required to draw a solid conclusion regarding the role of GTX in HSCT recipients in desperate situations such as active fungal infections.

Entities:  

Keywords:  Anti-fungal treatment; Fungal infection; Granulocyte transfusion; Stem cell transplantation

Year:  2011        PMID: 22942564      PMCID: PMC3155722          DOI: 10.1007/s12288-011-0078-y

Source DB:  PubMed          Journal:  Indian J Hematol Blood Transfus        ISSN: 0971-4502            Impact factor:   0.900


  21 in total

Review 1.  Combination chemotherapy for invasive fungal infections: what laboratory and clinical studies tell us so far.

Authors:  Dimitrios P Kontoyiannis; Russell E Lewis
Journal:  Drug Resist Updat       Date:  2003-10       Impact factor: 18.500

Review 2.  Granulocyte transfusion therapy.

Authors:  Thomas H Price
Journal:  J Clin Apher       Date:  2006-04       Impact factor: 2.821

3.  Aspergillosis prior to bone marrow transplantation. Infectious Diseases Working Party of the EBMT and the EORTC Invasive Fungal Infections Cooperative Group.

Authors:  C Cordonnier; J Beaune; F Offner; A Marinus; P Ljungman; F Meunier
Journal:  Bone Marrow Transplant       Date:  1995-08       Impact factor: 5.483

Review 4.  The role of granulocyte transfusions in neutropenic patients.

Authors:  M Bishton; R Chopra
Journal:  Br J Haematol       Date:  2004-12       Impact factor: 6.998

5.  Cataracts in neutrophil donors stimulated with adrenal corticosteroids.

Authors:  Z Ghodsi; R G Strauss
Journal:  Transfusion       Date:  2001-12       Impact factor: 3.157

6.  In vitro activity of combination therapy with cefepime, piperacillin-tazobactam, or meropenem with ciprofloxacin against multidrug-resistant Pseudomonas aeruginosa strains.

Authors:  Ilknur Erdem; Metin Kucukercan; Nurgul Ceran
Journal:  Chemotherapy       Date:  2003-12       Impact factor: 2.544

7.  Granulocyte transfusions for neutropenic patients with life-threatening infections: a single centre experience in 47 patients, who received 348 granulocyte transfusions.

Authors:  Y Ofran; I Avivi; A Oliven; I Oren; T Zuckerman; L Bonstein; J M Rowe; E J Dann
Journal:  Vox Sang       Date:  2007-11       Impact factor: 2.144

8.  Outcome determinants of fusariosis in a tertiary care cancer center: the impact of neutrophil recovery.

Authors:  D P Kontoyiannis; G P Bodey; H Hanna; R Hachem; M Boktour; E Girgaway; M Mardani; I I Raad
Journal:  Leuk Lymphoma       Date:  2004-01

9.  Granulocyte transfusions from G-CSF-stimulated donors for the treatment of severe infections in neutropenic pediatric patients with onco-hematological diseases.

Authors:  Simone Cesaro; Pierangelo Chinello; Giustina De Silvestro; Piero Marson; Giorgio Picco; Stefania Varotto; Silvia Pittalis; Luigi Zanesco
Journal:  Support Care Cancer       Date:  2002-11-12       Impact factor: 3.603

Review 10.  Minimizing the risk of recurrent or progressive invasive mold infections during stem cell transplantation or further intensive chemotherapy.

Authors:  A Grigg; M Slavin
Journal:  Transpl Infect Dis       Date:  2007-07-01       Impact factor: 2.228

View more
  1 in total

Review 1.  Granulocyte transfusions in the management of invasive fungal infections.

Authors:  Kamille A West; Juan Gea-Banacloche; David Stroncek; Sameer S Kadri
Journal:  Br J Haematol       Date:  2017-03-14       Impact factor: 6.998

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.